BRAF and non-small cell lung carcinoma: These found have led to the development approval of three BRAF inhibitors as well as five combinations of a BRAF inhibitor to manage cancer such as anaplastic thyroid cancer, melanoma, non-small cell lung cancer and colorectal cancer [18].